Abstract: Disclosed herein is a once-through heat exchanger that includes a tube stack including a plurality of tubes, a plurality of heads connected to the tube stack via a connection module and configured to accommodate heated steam, the connector module comprising a plurality of tube connectors and configured to connect the tubes and the heads, and a manifold connected to the heads via a plurality of link pipes and configured to accommodate heated steam, wherein the connector module comprises a first tube connector and a second tube connector having different shapes.

Abstract: The present invention relates to a method for culturing a 3-dimensional lung cancer organoid and a method for preparing a patient-derived xenograft animal model using the same. More specifically, the present invention relates to a method for culturing a 3-dimensional lung cancer organoid, a lung cancer organoid prepared by the method, a medium composition for culturing the lung cancer organoid, a method for preparing a xenograft animal model using the lung cancer organoid, a patient-derived lung cancer organoid xenograft animal model prepared by the method, and a method for analyzing therapeutic efficacy of an anticancer agent and a method for screening an anticancer agent, using the animal model.

Abstract: A software package, a gateway for transmitting the same, and a software update method using the same are provided. A software package includes a binary file, a configuration file, and a hash file. The binary file includes read-only memory (ROM) data of a target controller. A management server generates the configuration file by combining a hash value obtained by hashing the binary file with meta information indicating an update procedure between a gateway and the target controller. The management server generates the hash file by hashing the configuration file. The gateway receives the software package and extract the binary file and the configuration file. The gateway transmits the binary file to the target controller according to the update procedure indicated by the meta information.

Abstract: A vehicular software update system for remotely performing a software update of a vehicle and a method thereof are provided. The vehicular software update system includes a management controller installed in a vehicle and a server that performs a remote software update in cooperation with the management controller. The management controller controls the vehicle to start in response to receiving a request for the remote software update from the server, downloads software for update from the server after controlling the vehicle to start, transmits the downloaded software for update to a performance controller in the background, determines whether the transmission of the software for update in the background is completed based on the vehicle being turned off, and performs a software update of the performance controller using the software for update based on the transmission of the software for update in the background being completed.

Abstract: An electronic device includes a display device, which may be fabricated using a described method. The display device includes a glass substrate including a first surface, a second surface opposite the first surface, and a side surface between the first surface and the second surface, an outermost structure on the first surface of the glass substrate and located adjacent to an edge of one side of the glass substrate, and a display area including a plurality of light emitting areas on the first surface of the glass substrate and located farther from the edge of the one side of the glass substrate than the outermost structure is. A minimum distance from the side surface of the glass substrate to the outermost structure is equal to 130 ?m or less.

Abstract: A vehicular software update system includes a management controller coupled to a vehicle and at least one performance controller that receives software for over-the-air (OTA) update in the background from the management controller. The management controller determines a network load of the vehicle and adjusts a transmission speed of the software for OTA update, the software being transmitted to the at least one performance controller, based on a driving state of the vehicle and the network load of the vehicle.

Abstract: Disclosed is a hydrogel preparation method using crosslinking structure control by electron beam irradiation and a hydrogel prepared by the same, and the hydrogel preparation method includes: (A) mixing two or more natural polysaccharides and a solvent at room temperature to prepare a preliminary hydrogel composition; (B) heating the preliminary hydrogel composition to a predetermined temperature or higher to cause the preliminary hydrogel composition to be loosened linearly with respect to a chain-coil structure of the natural polysaccharides, resulting in uniform mixing; (C) lowering the temperature of the preliminary hydrogel composition to room temperature to gel the preliminary hydrogel composition into a hydrogel, and allowing the two or more natural polysaccharides to form a mesh structure by chain entanglement to form an Interpenetrating Polymer Network (IPN) structure; and (D) selectively irradiating the hydrogel with a high-energy electron beam to control a crosslinking structure by using chain scis

Abstract: A composition contains Phragmitis Rhizoma extract as an active ingredient. As a result of treating mouse bone marrow cells with an extract of Phragmitis Rhizoma, it was confirmed to have an effect that a decrease in colony of hematopoietic cells, which is induced by an anticancer agent, is significantly recovered and bone marrow suppression caused by an anticancer agent is significantly recovered in an animal model which has been induced to have bone marrow suppression according to intraperitoneal injection of an anticancer agent. Thus, the Phragmitis Rhizoma extract can be advantageously used for a composition for prevention, amelioration, or treatment of a disorder caused by side effect of an anticancer agent, and there is a possibility of having the increased effect of an anticancer agent when it is used as an anticancer adjuvant in combination with an anticancer agent.

Abstract: The present invention relates to a method for preparing 3,6-anhydro-L-galactose, and use thereof. More specifically, 3,6-anhydro-L-galactose, which is a monosaccharide constituting agar, is produced in a high yield through chemical and enzymatic methods, and the physiological activities thereof such as whitening, moisturizing, antioxidant, antiinflammatory activities and the like are displayed, thereby enabling industrial use thereof.

Abstract: The present invention relates to a method for preparing 3,6-anhydro-L-galactose, and use thereof. More specifically, 3,6-anhydro-L-galactose, which is a monosaccharide constituting agar, is produced in a high yield through chemical and enzymatic methods, and the physiological activities thereof such as whitening, moisturizing, antioxidant, antiinflammatory activities and the like are displayed, thereby enabling industrial use thereof.

Abstract: The present invention relates to a method for preparing 3,6-anhydro-L-galactose, and use thereof. More specifically, 3,6-anhydro-L-galactose, which is a monosaccharide constituting agar, is produced in a high yield through chemical and enzymatic methods, and the physiological activities thereof such as whitening, moisturizing, antioxidant, anti-inflammatory activities and the like are displayed, thereby enabling industrial use thereof.

Abstract: The present invention relates to a method for preparing 3,6-anhydro-L-galactose, and use thereof. More specifically, 3,6-anhydro-L-galactose, which is a monosaccharide constituting agar, is produced in a high yield through chemical and enzymatic methods, and the physiological activities thereof such as whitening, moisturizing, antioxidant, anti-inflammatory activities and the like are displayed, thereby enabling industrial use thereof.

Abstract: The present invention relates to a method for preparing 3,6-anhydro-L-galactose, and use thereof. More specifically, 3,6-anhydro-L-galactose, which is a monosaccharide constituting agar, is produced in a high yield through chemical and enzymatic methods, and the physiological activities thereof such as whitening, moisturizing, antioxidant, anti-inflammatory activities and the like are displayed, thereby enabling industrial use thereof.

Abstract: The present invention relates to a composition for preventing or treating colon cancer, containing 3,6-anhydro-L-galactose, and more specifically, provides excellent anti-cancer effects by inducing apoptosis of colon cancer cells and inhibiting the growth of colon cancer cells by using 3,6-anhydro-L-galactose separated from red algae-derived agar and purified.

Abstract: The present invention relates to a method for preparing 3,6-anhydro-L-galactose, and use thereof. More specifically, 3,6-anhydro-L-galactose, which is a monosaccharide constituting agar, is produced in a high yield through chemical and enzymatic methods, and the physiological activities thereof such as whitening, moisturizing, antioxidant, anti-inflammatory activities and the like are displayed, thereby enabling industrial use thereof.

Abstract: Disclosed is a pharmaceutical composition for treating and preventing metabolic bone diseases, comprising a pharmaceutically effective amount of N-acylated lysophosphatidylcholine compound represented by Formula 1 (R is a saturated or unsaturated fatty acid of C14 to C20, and R? is methoxycarbonyl or hydroxylmethyl group), and a pharmaceutically acceptable carrier. Also, the present invention discloses a method of preparing an N-acylated lysophosphatidylcholine compound represented by Formula 1, from serine.